Literature DB >> 15592707

[Chemotherapy for germ cell cancer].

J Beyer1, C Bokemeyer.   

Abstract

Chemotherapy for germ cell cancer is usually indicated in patients who present with metastatic disease, suffer relapses, or progress after their initial treatment. Rarely is chemotherapy needed in the palliative treatment of refractory patients. However, more recently chemotherapy has been demonstrated to benefit also patients with early stages of seminoma as well as nonseminoma. Therefore, the most recent European consensus guidelines on treatment and diagnosis of germ cell cancer list chemotherapy as an alternative treatment option in the early tumor stages I and II. The application of chemotherapy represents a challenge for both patients and the treating physician who must be experienced with a broad array of chemotherapy regimens and competent in their application. Particularly the treatment of patients with advanced tumor stages requires good clinical skills on the part of the treating oncologist. If excessive toxicity is to be avoided and a curative treatment option maintained, overtreatment as well as undertreatment are notorious pitfalls.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592707     DOI: 10.1007/s00120-004-0704-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

Review 1.  [Late toxicity after chemotherapy of malignant testicular tumors].

Authors:  A Jakob; C Kollmannsberger; L Kanz; C Bokemeyer
Journal:  Urologe A       Date:  1998-11       Impact factor: 0.639

2.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Authors:  S D Fosså; S B Kaye; G M Mead; M Cullen; R de Wit; I Bodrogi; C J van Groeningen; P H De Mulder; S Stenning; E Lallemand; L De Prijck; L Collette
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.

Authors:  C Kollmannsberger; C Nichols; C Meisner; F Mayer; L Kanz; C Bokemeyer
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

5.  Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

Authors:  H-J Schmoll; C Kollmannsberger; B Metzner; J T Hartmann; N Schleucher; P Schöffski; J Schleicher; O Rick; J Beyer; D Hossfeld; L Kanz; W E Berdel; R Andreesen; C Bokemeyer
Journal:  J Clin Oncol       Date:  2003-10-20       Impact factor: 44.544

6.  [Testicular tumors. Mortality and recurrence after inadequate therapy].

Authors:  P Albers; K Dommer; S C Müller
Journal:  Urologe A       Date:  1998-11       Impact factor: 0.639

Review 7.  Recent strategies for the use of paclitaxel in the treatment of urological malignancies.

Authors:  C Bokemeyer; J T Hartmann; M A Kuczyk; M C Truss; C Kollmannsberger; J Beyer; U Jonas; L Kanz
Journal:  World J Urol       Date:  1998       Impact factor: 4.226

8.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

Review 9.  The role of high-dose chemotherapy in relapsed germ cell tumors.

Authors:  O Rick; C Kollmannsberger; J T Hartmann; T Braun; W Siegert; C Bokemeyer; J Beyer
Journal:  World J Urol       Date:  2004-03-18       Impact factor: 4.226

10.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more
  6 in total

Review 1.  [High-dose chemotherapy and hematopoietic stem cell transplantation in patients with germ cell cancer].

Authors:  L Weissbach; J Beyer
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

Review 2.  [Diagnosis, treatment and follow-up of testicular cancer].

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2017-12       Impact factor: 0.639

Review 3.  [Aftercare in testicular cancer is worthwhile. Recurrences are curable].

Authors:  T S Pottek; K-P Dieckmann
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 4.  [Diagnostics and treatment of seminomatous germ cell tumors].

Authors:  F Zengerling; J Müller; S Krege; M Schrader
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

5.  [Diagnosis and treatment of nonseminomatous germ cell tumors].

Authors:  S Krege
Journal:  Urologe A       Date:  2013-12       Impact factor: 0.639

Review 6.  Review of Testicular Tumor: Diagnostic Approach and Management Outcome in Africa.

Authors:  Ayun Cassell; Mohamed Jalloh; Medina Ndoye; Bashir Yunusa; Mouhamadou Mbodji; Abdourahmane Diallo; Omar Gaye; Issa Labou; Lamine Niang; Serigne Gueye
Journal:  Res Rep Urol       Date:  2020-02-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.